Title:
非常に高い皮膚浸透率を有するレチノイド及びレチノイド様化合物の正に荷電した水溶性プロドラッグ
Document Type and Number:
Japanese Patent JP5826459
Kind Code:
B2
Abstract:
The novel positively charged pro-drugs of retinoids and retinoid-like compounds in the general formula (31) 'Structure 31' were designed and synthesized. The compounds of the general formula (31) 'Structure 31' indicated above can be prepared from retinoic acids and related compounds, by reaction with suitable alcohols, thiols, or amines and coupling reagents, such as N, N'-Dicyclohexylcarbodiimide, N,N'-Diisopropylcarbodiimide, O- (Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate, O- (Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, Benzotriazol- 1-yl-oxy-tris(dimethylamino)phosphonium hexafluorophosphate, et al. The positively charged amino groups of these pro-drugs not only largely increases the solubility of the drugs in water, but also bonds to the negative charge on the phosphate head group of membranes. This bonding will disturb the membrane a little bit and may make some room for the lipophilic portion of the prodrug. When the molecules of membrane move, the membrane may 'crack' a little bit due to the bonding of the prodrug. This will let the prodrug insert into the membrane. At pH 7.4, only about 99% of amino group is protonated. When the amino group is not protonated, the bonding between the amino group of the prodrug and the phosphate head group of membrane will disassociate, and the prodrug will enter the membrane completely. When the amino group of the prodrug flips to the other side of the membrane and thus become protonated, then the prodrug is pulled into the cytosol, a semiliquid concentrated aqueous solution or suspension. The results suggest that the pro-drugs diffuse through human skin -350 times faster than do retinoids and retinoid-like compounds. In plasma, more than 90% of these pro-drugs can change back to the parent drugs in a few minutes. The prodrugs can be used medicinally in treating any retinoids and retinoid-like compounds-treatable conditions in humans or animals. The prodrugs can be administered transdermally for any kind of medical treatments and avoid most of the side effects of retinoids and retinoid-like compounds. Controlled transdermal administration systems of the prodrug enables retinoids and retinoid-like compounds to reach constantly optimal therapeutic blood levels to increase effectiveness and reduce the side effects of retinoids and retinoid-like compounds. Another great benefit of transdermal administration of these pro-drugs is that administering medication, especially to children, will be much easier.
More Like This:
Inventors:
You Chongshi
Application Number:
JP2009545245A
Publication Date:
December 02, 2015
Filing Date:
January 15, 2007
Export Citation:
Assignee:
You Chongshi
International Classes:
C07C403/20; C07C403/18
Domestic Patent References:
| JP63101347A |
Foreign References:
| US3950418 | ||||
| US5972323 |
Attorney, Agent or Firm:
Koichi Tsujii
Sadao Kumakura
Atsushi Hakoda
Kenji Asai
Kazuo Yamazaki
Satsuki Ichikawa
Hironobu Hattori
Sadao Kumakura
Atsushi Hakoda
Kenji Asai
Kazuo Yamazaki
Satsuki Ichikawa
Hironobu Hattori